Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Completed · Phase 3 · Has a placebo group

Conditions studied: Rosacea

In brief

Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once daily is more efficacious than vehicle and provides an acceptable safety profile in the treatment of facial erythema associated with rosacea.

Key facts

Study ID

NCT01355458

Run by

Galderma R&D

People needed

260

Starts

2011-05-01

Expected to finish

2011-12-01

Last updated by the study team

2021-02-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Dermatology Research Associates — Los Angeles, California, United States
• University of California, San Francisco — San Francisco, California, United States
• Michigan Center for Skin Care Research — Clinton Township, Michigan, United States
• Windsor Dermatology — East Windsor, New Jersey, United States
• Dermatology Consulting Services — High Point, North Carolina, United States
• Oregon Medical Research Center — Portland, Oregon, United States
• Philadelphia Institute of Dermatology — Fort Washington, Pennsylvania, United States
• The Skin Wellness Center — Knoxville, Tennessee, United States
• Arlington Center for Dermatology — Arlington, Texas, United States
• DermResearch, Inc. — Austin, Texas, United States
• Dermatology Treatment & Research Center — Dallas, Texas, United States
• The Education & Research Foundation, Inc. — Lynchburg, Virginia, United States
• Lynderm Research Inc — Markham, Ontario, Canada
• Windsor Clinical Research Inc. — Windsor, Ontario, Canada
• Innovaderm Research, Inc — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.